ClinicalTrials.gg
Status unknownNCT03300115Updated Feb 19, 2019

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

A Phase 2 interventional study of AC0010 in Metastatic Non-small Cell Lung Cancer, sponsored by Hangzhou ACEA Pharmaceutical Research Co., Ltd.. Status unknown at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-02-19.

Sponsored by Hangzhou ACEA Pharmaceutical Research Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2017, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 987 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
481st of 1,595
222 · median 100
Started
2017
with 82 others
Phase 2
652 of 1,882
274 open now
Registered
417th of 1,882
by date

Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 481st largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 83 that started in 2017, is one of 652 in phase 2, and was the 417th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

762 of the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

757 more — sign in →

All 762 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the study drug's efficacy and safety.

Read the detailed description

The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand the sample size based on the fixed dose recommended by the results of previous dose exploration studies in order to further evaluate the study drug's efficacy and safety with overall objective tumor response rate (ORR) as the primary efficacy evaluation indicator, and further evaluate subjects' duration of response (DOR), progression-free survival (PFS), disease control rate (DCR), overall survival (OS) and quality of life (QoL). Safety indicators of subjects are further evaluated through adverse events, vital signs and clinical laboratory parameters.

03

Conditions studied

  • Metastatic Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-75 years (including 18 and 75 years old).
  2. or cytologically confirmed or unresectable locally advanced, recurrent non-small cell lung cancer which cannot receive radical surgery and radiotherapy.
  3. The patient has at least one radio graphically (CT, MRI) according to the criteria for solid tumor response; long-diameter of tumor scanned by CT\&MRI ≥10mm, or short-diameter of metastatic cervical lymph nodes≥15mm. With no radiotherapy and .
  4. Patients without or asymptomatic patients with brain metastases. The number of CNS metastases focus≤2, maximum diameter \<10mm.
  5. Document prove EGFR mutation before treatment of EGFR TKI, or show clinical benefit after treatment of EGFR TKI (PR, CR evaluation according to RECIST or more than half-year SD duration); tumor tissue proved to be EGFR T790M positive mutation by center lab after last treatment.
  6. Patients need to undergo biopsy of primary or metastatic tumor tissue and provide pathological sections to site's central lab; otherwise, the patients need to undergo biopsy of primary or metastatic tumor tissue in the screening period and provide pathological sections to the site's central laboratory.
  7. Patients who have previously received first-generation EGFR-TKI (erlotinib, gefitinib, ectectin) treatment and developed resistance and are only allowed to have received one chemotherapy regimen (maintenance treatment with the same drug is allowed; but maintenance treatment with a different drug is not allowed), or are positive for primary T790M mutation but have not received treatment or have only received treatment.
  8. The patient must have good organ function, including meeting the laboratory test requirements at screening.
  9. Patients must recover to ≤Grade 1 ( v4.03)toxicity from the previous treatment (patients with any grade of hair loss are allowed to enter the study).
  10. score: 0-1 points. No deterioration in the last 2 weeks.
  11. Expected survival time:> 12 weeks.
  12. Patients who can cooperate with the observation of adverse events and efficacy.
  13. Patients or their legal representatives have signed a written form.

Exclusion criteria

Exclusion Criteria:

  1. Acute , chronic hepatitis C and active (positive HBsAg; HBcAb or HBeAb positive and HBV DNA positive).
  2. antibody positive, or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.
  3. A past history of interstitial lung disease and radiation pneumonia.
  4. abnormalities of resting in rhythm, conduction and morphology, such as complete left bundle branch block, Grade II and above heart block, PR interval> 250 ms, or myocardial infarction within the past 6 months; there are risk factors leading to prolongation of or increasing arrhythmias, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or medical history of sudden death at an age of \< 40 years among the patient's first-degree relatives, and 12-lead ECG QT interval correction Fridericia method (QTcF interval)> 450 ms for male, >470ms for female.
  5. The investigator judges based on safety concerns or clinical study process that the patient had any other condition that is prohibited for participation in the clinical study, such as severe infection/inflammation, intestinal obstruction, inability to swallow medication, social/psychological problems, etc.

    With clinically significant electrolyte abnormalities in laboratory tests;

  6. In addition to NSCLC, patients who have been diagnosed with another and/or treatment-requiring malignant disease in recent 5 years (this exclusion criterion does not include the following circumstances: completely resected basal cell and squamous cell skin cancer, inert malignant tumor currently requiring no treatment, and any type of completely resected carcinoma in situ).

    Patients who have used high-dose or other agents within 1 month prior to screening.

  7. Interval time between previous EGFR TKI treatment and AC0010 \<8 days or 5 half-time, subject to the long time; Interval time between major surgery /radiotherapy and AC0010 \<4 weeks; Patients who are using any drug known to prolong QT interval or known potent enzyme inducer or inhibitor within 4 weeks before the first dose.

    Patients who have used high-dose glucocorticoids or other immunosuppressive agents within 1 month prior to screening.

  8. Patients who have previously administered third-generation EGFR-TKI drugs (e.g.,AZD9291, Avitinib, CO-1686, HM61713, etc.).
  9. Patients who have been registered and received the study treatment or withdrawn from the study cannot be enrolled.
  10. Pregnant or lactating women.
  11. Women with are defined as all women who are physiologically able to have a pregnancy, unless they are using an efficient method during treatment and within 7 days after discontinuation of treatment.
  12. Patients who are considered by the investigator as inappropriate to participate in the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    AC0010

    Each participant will be given AC0010 300mg bid.

    Drug: AC0010

Interventions

  • DrugAbivertinibStudies of AbivertinibAbivertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).

    Also known as: AC0010MA

06

What researchers measure

Primary outcomes

  1. ORR(Objective Response Rate)

    To assess the overall objective response rate (ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).

    Time frame: Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

Secondary outcomes

  1. DoR (Duration of Response)

    To assess the duration of response (DOR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).

    Time frame: Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  2. PFS (Progression-free survival)

    To assess the progression-free survival (PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).

    Time frame: Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  3. DCR (Disease control rate)

    To assess the disease control rate (DCR) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).

    Time frame: Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  4. OS (Overall survival)

    To assess the overall survival (OS) of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).

    Time frame: Every 6 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

  5. The lung cancer symptoms and health-related quality of life (HRQoL)

    To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced non-small cell lung cancer (NSCLC).

    Time frame: Every 3 weeks from time of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

07

Study locations

25 of 25 sites recruiting
  • Beijing Cancer Hospital
    Beijing, Beijing 100000, China
    Recruiting
    • Jian Fang · Contact
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100000, China
    Recruiting
    • Junling Li · Contact
  • Chinese PLA General Hospital
    Beijing, Beijing 100000, China
    Recruiting
    • Zhefeng Liu · Contact
  • Daping Hospital,Research Institute of Surgery Third Military Medical University
    Chongqing, Chongqing 400000, China
    Recruiting
    • Yong He · Contact
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350000, China
    Recruiting
    • Cheng Huang · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Yilong Wu · Contact
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530000, China
    Recruiting
    • Guosheng Feng · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
    Recruiting
    • Yanqiu Zhao · Contact
  • Tongji Medical College of HUST
    Wuhan, Hubei 430000, China
    Recruiting
    • Yuan Chen · Contact
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430000, China
    Recruiting
    • Conghua Xie · Contact
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
    Recruiting
    • Peiguo Cao · Contact
  • Xiangya Hospital Central South University
    Changsha, Hunan 410000, China
    Recruiting
    • Chengping Hu · Contact
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
    Recruiting
    • Jian'an Huang · Contact
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
    Recruiting
    • Buhai Wang · Contact
  • Jilin Cancer Hospital
    Chang chun, Jilin 130000, China
    Recruiting
    • Ying Cheng · Contact
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
    Recruiting
    • Jiuwei Cui · Contact
  • Shandong Cancer Hospital
    Jinan, Shandong 250000, China
    Recruiting
    • Zhehai Wang · Contact
  • Tangdu Hospital
    Xi'an, Shanxi 710000, China
    Recruiting
    • Helong Zhang · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610000, China
    Recruiting
    • Zongan Liang · Contact
    • Zongan Liang · Principal investigator
    • Jiang Zhu · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300000, China
    Recruiting
    • Changli Wang · Contact
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300000, China
    Recruiting
    • Jun Chen · Contact
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Limin Wang · Contact
  • Sir Run Run Shaw Hospital,Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Hongming Pan · Contact
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Jianjin Huang · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Yiping Zhang · Contact
    • Yun Fan · Principal investigator
    • Yiping Zhang · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2017 (actual). Primary completion is estimated for Jun 2019, 24 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 3, 2017
StartActual
May 18, 2017
Primary completionEst.
Jun 17, 2019
CompletionEst.
Dec 17, 2020
Last update
Feb 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03300115
Lead sponsor
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
May 18, 2017
Primary completion
Jun 17, 2019 (estimated)
Completion
Dec 17, 2020 (estimated)
Last update
Feb 19, 2019

Study contacts

Wanhong Xu, PhD
Contact
kayla.liu@aceapharma.com
+8657128908600
Yilong Wu, MD
principal investigator · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abivertinib

Start the discussion